PFE and AMGN Related Headlines
Go Back- U.S. biopharma earnings: Eli Lilly (LLY), Pfizer (PFE) take the stage
- The Next Generation of the GLP-1 Revolution Is Already Underway
- FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'
- Barclays launches U.S. biopharma coverage with four preferred picks
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
- Trump to announce prescription drug price agreements
- Bernstein on IRA pricing: $245 really is the floor
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
- U.S. Government's Announcement On Pharma Sector Probe And Tariffs Unlikely For A Few Weeks, Sources Say - Reuters
PFE and AMGN Related Press Releases
Go Back- The Next Generation of the GLP-1 Revolution Is Already Underway
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
